oral luteoin treatment in localized prostate cancer receiving active surveillance

Efficacy of oral luteoin treatment in localized prostate cancer receiving active surveillance in mult-institutional study - Efficacy in luteolin in AS

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs041250158

Enrollment

Registered

2026-01-08

Start date

2026-01-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

In cases occurred with severe adverse events, or rapid worsening of prostate cancer localized prostate cancer

Interventions

50mg /day oral luteolin treatment in one year

luteolin

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1. patients receiving active surveillance 2. initial PSA less than 20, less than cT2b 3. patients obtained informed consent 4. male patients whose age is more than 20 5. ECOG-PS less than 1

Exclusion criteria

Exclusion criteria: 1. patients with dimentia 2. patients with serious infection 3. patients with hepatic dyscunction (Child-Pugh criteria B, C) 4. patients with severe renal dysfunction 5. patients with inadequate designated by responsible doctor

Design outcomes

Primary

Measure	Time frame
rate of worsening of prostate cancer under active surveillance	—

Secondary

Measure	Time frame
adverse events, or microRNA status	—

Contacts

Public ContactTaku Naiki

Nagoya City University West Medical Center

naiki@med.nagoya-cu.ac.jp+81-52-991-8121

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026